MOG and myeloid sarcoma: This variability in results can be attributed to differences in study designs, including the use of gonadectomized animals, prophylactic treatment protocols, and diverse MS mouse models such as PLP-RR EAE, MOG-induced EAE, CPZ-induced demyelination, and acute lysolecithin demyelinating models.